{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:38:15Z","timestamp":1782779895954,"version":"3.54.5"},"reference-count":57,"publisher":"Becaris Publishing Limited","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            Real-world evidence comparing healthcare resource utilization (HRU) and costs between ibrutinib and acalabrutinib, two Bruton\u2019s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL\/SLL) is limited.\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            Commercial claims from IQVIA PharMetrics Plus and electronic medical records from Acentrus were used to separately evaluate HRU and costs in CLL\/SLL patients initiating first-line (1L) single-agent ibrutinib or acalabrutinib on or after 21 November 2019 (index date). Imputed costs were used for Acentrus using previously published assumptions. Regression analyses adjusted for baseline characteristics were used to compare HRU and costs between ibrutinib and acalabrutinib during 1L therapy.\n            <jats:bold>Results:<\/jats:bold>\n            In IQVIA, 537 and 355 patients initiated 1L ibrutinib and acalabrutinib, respectively; in Acentrus, 710 and 373 patients initiated 1L ibrutinib and acalabrutinib, respectively. The mean duration of 1L (in years) was longer for ibrutinib (IQVIA: 1.2; Acentrus: 1.3) than acalabrutinib (IQVIA: 0.8; Acentrus: 0.9). The number of CLL\/SLL-related outpatient visits were significantly lower for ibrutinib versus acalabrutinib (IQVIA: 0.86 vs 1.09 per-patient-per-month, rate ratio: 0.85, p\u00a0=\u00a00.018; Acentrus: 0.57 vs 0.74 per-patient-per-month, rate ratio: 0.80, p\u00a0=\u00a00.036). Using claims data for IQVIA and imputed costs for Acentrus, total all-cause costs (IQVIA: mean monthly cost difference [MMCD]: -$764, p\u00a0=\u00a00.279; Acentrus: MMCD: -$1355, p\u00a0=\u00a00.004) and CLL\/SLL related costs (IQVIA: MMCD: -$649, p\u00a0=\u00a00.133; Acentrus: MMCD: -$1215, p\u00a0=\u00a00.004) were lower for ibrutinib versus acalabrutinib.\n            <jats:bold>Conclusion:<\/jats:bold>\n            In this large real-world study using a mix of claims data and imputed cost estimates, CLL\/SLL patients treated with ibrutinib had longer duration of 1L, fewer days with CLL\/SLL-related outpatient services and numerically lower all-cause and CLL\/SLL-related costs versus acalabrutinib, showing that ibrutinib can be an optimal cost-effective option in 1L.\n          <\/jats:p>","DOI":"10.57264\/cer-2024-0210","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T14:51:46Z","timestamp":1745333506000},"source":"Crossref","is-referenced-by-count":2,"title":["A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases"],"prefix":"10.57264","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5748-7874","authenticated-orcid":false,"given":"Kerry A","family":"Rogers","sequence":"first","affiliation":[{"name":"Division of Hematology, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2387-6676","authenticated-orcid":false,"given":"Benyam","family":"Muluneh","sequence":"additional","affiliation":[{"name":"Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9605-3980","authenticated-orcid":false,"given":"Zaina P","family":"Qureshi","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC, a Johnson &amp; Johnson company, Horsham, PA 19044, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghua","family":"He","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC, a Johnson &amp; Johnson company, Horsham, PA 19044, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Bokun","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC, a Johnson &amp; Johnson company, Horsham, PA 19044, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Ding","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC, a Johnson &amp; Johnson company, Horsham, PA 19044, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Lafeuille","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Montr\u00e9al, QC H3B 0G7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4462-8591","authenticated-orcid":false,"given":"Priyanka","family":"Gogna","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Montr\u00e9al, QC H3B 0G7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0060-765X","authenticated-orcid":false,"given":"Bruno","family":"Emond","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Montr\u00e9al, QC H3B 0G7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fradley","sequence":"additional","affiliation":[{"name":"Thalheimer Center for Cardio-Oncology, Abramson Cancer Center &amp; Division of Cardiology, Hospital of the University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"e_1_3_8_3_2","unstructured":"National Cancer Institute Surveillance Epidemiology and End Results Program. Cancer stat facts: leukemia \u2014 chronic lymphocytic leukemia (CLL) 2025 [cited: 28 March 2025]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html"},{"key":"e_1_3_8_4_2","unstructured":"American Cancer Society. Key statistics for chronic lymphocytic leukemia 2025. Available from: https:\/\/www.cancer.org\/cancer\/types\/chronic-lymphocytic-leukemia\/about\/key-statistics.html"},{"issue":"1","key":"e_1_3_8_5_2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-021-01054-w","article-title":"Current and future treatment strategies in chronic lymphocytic leukemia","volume":"14","author":"Patel K","year":"2021","unstructured":"Patel K, Pagel JM. Current and future treatment strategies in chronic lymphocytic leukemia. J. Hematol. Oncol. 14(1), 69 (2021).","journal-title":"J. Hematol. Oncol."},{"issue":"11","key":"e_1_3_8_6_2","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr PM","year":"2022","unstructured":"Barr PM, Owen C, Robak T Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 6(11), 3440\u20133450 (2022).","journal-title":"Blood Adv."},{"issue":"13","key":"e_1_3_8_7_2","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1080\/10428194.2020.1795159","article-title":"Final 5-year findings from the phase III HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"61","author":"Fraser GAM","year":"2020","unstructured":"Fraser GAM, Chanan-Khan A, Demirkan F Final 5-year findings from the phase III HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma. Leuk. Lymphoma 61(13), 3188\u20133197 (2020).","journal-title":"Leuk. Lymphoma"},{"issue":"9","key":"e_1_3_8_8_2","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.3324\/haematol.2021.279012","article-title":"First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial","volume":"107","author":"Moreno C","year":"2022","unstructured":"Moreno C, Greil R, Demirkan F First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. Haematologica 107(9), 2108\u20132120 (2022).","journal-title":"Haematologica"},{"issue":"2","key":"e_1_3_8_9_2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt TD","year":"2022","unstructured":"Shanafelt TD, Wang XV, Hanson CA Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood 140(2), 112\u2013120 (2022).","journal-title":"Blood"},{"issue":"1","key":"e_1_3_8_10_2","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1182\/blood-2021-153146","article-title":"Long-term results of Alliance A041202 show continued advantage of ibrutinib-based regimens compared with bendamustine plus rituximab (br) chemoimmunotherapy","volume":"138","author":"Woyach JA","year":"2021","unstructured":"Woyach JA, Ruppert AS, Heerema NA Long-term results of Alliance A041202 show continued advantage of ibrutinib-based regimens compared with bendamustine plus rituximab (br) chemoimmunotherapy. Blood 138(Suppl. 1), 639 (2021).","journal-title":"Blood"},{"issue":"3","key":"e_1_3_8_11_2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase III RESONATE-2 study","volume":"34","author":"Burger JA","year":"2020","unstructured":"Burger JA, Barr PM, Robak T Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase III RESONATE-2 study. Leukemia 34(3), 787\u2013798 (2020).","journal-title":"Leukemia"},{"issue":"1","key":"e_1_3_8_12_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase III trial","volume":"20","author":"Moreno C","year":"2019","unstructured":"Moreno C, Greil R, Demirkan F Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase III trial. Lancet Oncol. 20(1), 43\u201356 (2019).","journal-title":"Lancet Oncol."},{"issue":"5","key":"e_1_3_8_13_2","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt TD","year":"2019","unstructured":"Shanafelt TD, Wang XV, Kay NE Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N. Engl. J. Med. 381(5), 432\u2013443 (2019).","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"e_1_3_8_14_2","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach JA","year":"2018","unstructured":"Woyach JA, Ruppert AS, Heerema NA Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N. Engl. J. Med. 379(26), 2517\u20132528 (2018).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_8_15_2","volume-title":"Prescribing Information","author":"CALQUENCE (acalabrutinib)","year":"2022","unstructured":"CALQUENCE (acalabrutinib). Prescribing Information. AstraZeneca Pharmaceuticals LP, DE, USA (2022)."},{"key":"e_1_3_8_16_2","doi-asserted-by":"crossref","first-page":"S280","DOI":"10.1016\/S2152-2650(22)01350-7","article-title":"CLL-492 Real-world adherence to first-line ibrutinib and acalabrutinib single-agent among patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"22","author":"Lu X","year":"2022","unstructured":"Lu X, Emond B, Qureshi Z CLL-492 Real-world adherence to first-line ibrutinib and acalabrutinib single-agent among patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma. Clin. Lymph. Myeloma Leuk. 22, S280\u2013S281 (2022).","journal-title":"Clin. Lymph. Myeloma Leuk."},{"key":"e_1_3_8_17_2","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.2147\/PPA.S417180","article-title":"Real-world comparison of first-line treatment adherence between single-agent ibrutinib and acalabrutinib in patients with chronic lymphocytic leukemia","volume":"17","author":"Lu X","year":"2023","unstructured":"Lu X, Emond B, Morrison L Real-world comparison of first-line treatment adherence between single-agent ibrutinib and acalabrutinib in patients with chronic lymphocytic leukemia. Patient Pref. Adhere. 17, 2073\u20132084 (2023).","journal-title":"Patient Pref. Adhere."},{"key":"e_1_3_8_18_2","volume-title":"International Ultmann Chicago Lymphoma Symposium and Eurporean Hematology Association","author":"Jacobs R","year":"2024","unstructured":"Jacobs R, Levy M, Yazbeck V Comparison of time to next treatment between patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib, overall and in a subgroup with high-risk characteristics. Presented at: International Ultmann Chicago Lymphoma Symposium and Eurporean Hematology Association (2024)."},{"issue":"1","key":"e_1_3_8_19_2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2217\/fon-2023-0436","article-title":"Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib","volume":"20","author":"Jacobs R","year":"2024","unstructured":"Jacobs R, Lu X, Emond B Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib. Future Oncol. 20(1), 39\u201353 (2024).","journal-title":"Future Oncol."},{"issue":"7","key":"e_1_3_8_20_2","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1080\/10428194.2018.1554862","article-title":"Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL)","volume":"60","author":"Akhtar OS","year":"2019","unstructured":"Akhtar OS, Attwood K, Lund I Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL). Leuk. Lymphoma 60(7), 1650\u20131655 (2019).","journal-title":"Leuk. Lymphoma"},{"key":"e_1_3_8_21_2","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1182\/blood-2023-186284","article-title":"Ibrutinib dose adjustment does not impact time to next treatment in first-line patients with chronic lymphocytic leukemia: a real-world analysis of electronic medical records from academic and non-teaching hospitals using target trial emulation","volume":"142","author":"Ghosh N","year":"2023","unstructured":"Ghosh N, Qureshi ZP, Ding Z Ibrutinib dose adjustment does not impact time to next treatment in first-line patients with chronic lymphocytic leukemia: a real-world analysis of electronic medical records from academic and non-teaching hospitals using target trial emulation. Blood 142, 1915 (2023).","journal-title":"Blood"},{"key":"e_1_3_8_22_2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1182\/blood-2023-187743","article-title":"Comparative effectiveness of ibrutinib flexible dosing treatment strategies on time to next treatment in a largely community-based claims database: a target trial emulation study","volume":"142","author":"Ghosh N","year":"2023","unstructured":"Ghosh N, Wang R, Ding Z Comparative effectiveness of ibrutinib flexible dosing treatment strategies on time to next treatment in a largely community-based claims database: a target trial emulation study. Blood 142, 270 (2023).","journal-title":"Blood"},{"issue":"16","key":"e_1_3_8_23_2","doi-asserted-by":"crossref","first-page":"7538","DOI":"10.1200\/JCO.2023.41.16_suppl.7538","article-title":"Ibrutinib dose modifications for management of cardiac adverse events in patients with B-cell malignancies: pooled analysis of 10 clinical trials","volume":"41","author":"Stephens DM","year":"2023","unstructured":"Stephens DM, Brown JR, Shuo M Ibrutinib dose modifications for management of cardiac adverse events in patients with B-cell malignancies: pooled analysis of 10 clinical trials. J. Clin. Oncol. 41(Suppl. 16), 7538 (2023).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"e_1_3_8_24_2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3390\/cancers15020507","article-title":"Characteristics and clinical outcomes of patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma receiving ibrutinib for >\/= 5 years in the RESONATE-2 study","volume":"15","author":"Woyach JA","year":"2023","unstructured":"Woyach JA, Barr PM, Kipps TJ Characteristics and clinical outcomes of patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma receiving ibrutinib for >\/= 5 years in the RESONATE-2 study. Cancers (Basel) 15(2), 507 (2023).","journal-title":"Cancers (Basel)"},{"key":"e_1_3_8_25_2","volume-title":"European Hematology Association","author":"Shadman M","year":"2024","unstructured":"Shadman M, Karve S, Abbazio C P1846: real-world clinical outcomes of first-line ibrutinib dose reduction versus acalabrutinib among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Presented at: European Hematology Association, Madrid, Spain, 13\u201316 June 2024."},{"issue":"12","key":"e_1_3_8_26_2","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1080\/03007995.2020.1835851","article-title":"Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia","volume":"36","author":"Huang Q","year":"2020","unstructured":"Huang Q, Emond B, Lafeuille M-H Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia. Curr. Med. Res. Opin. 36(12), 2009\u20132018 (2020).","journal-title":"Curr. Med. Res. Opin."},{"issue":"12","key":"e_1_3_8_27_2","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.clml.2019.08.004","article-title":"Comparison of time to next treatment, health care resource utilization, and costs in patients with chronic lymphocytic leukemia initiated on front-line ibrutinib or chemoimmunotherapy","volume":"19","author":"Emond B","year":"2019","unstructured":"Emond B, Sundaram M, Romdhani H Comparison of time to next treatment, health care resource utilization, and costs in patients with chronic lymphocytic leukemia initiated on front-line ibrutinib or chemoimmunotherapy. Clin. Lymph. Myeloma Leuk. 19(12), 763\u2013775.e2 (2019).","journal-title":"Clin. Lymph. Myeloma Leuk."},{"key":"e_1_3_8_28_2","volume-title":"American Society of Hematology Annual Meeting","author":"Fradley M","year":"2022","unstructured":"Fradley M, Lafeuille MH, Emond B Early adherence and persistence to first-line ibrutinib or acalabrutinib among patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma and atrial fibrillation. Presented at: American Society of Hematology Annual Meeting, New Orleans, LA, USA, 10\u201313 December 2022."},{"issue":"1","key":"e_1_3_8_29_2","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/blood-2021-148155","article-title":"Majic: a phase III prospective, multicenter, randomized, open-label trial of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"138","author":"Davids M","year":"2021","unstructured":"Davids M, Mato A, Hum J Majic: a phase III prospective, multicenter, randomized, open-label trial of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Blood 138(Suppl. 1), 1553\u20131554 (2021).","journal-title":"Blood"},{"issue":"10","key":"e_1_3_8_30_2","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S1470-2045(21)00455-1","article-title":"Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase II study","volume":"22","author":"Davids M","year":"2021","unstructured":"Davids M, Lampson B, Tyekucheva S Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase II study. Lancet Oncol. 22(10), 1391\u20131402 (2021).","journal-title":"Lancet Oncol."},{"issue":"22","key":"e_1_3_8_31_2","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain N","year":"2019","unstructured":"Jain N, Keating M, Thompson P Ibrutinib and venetoclax for first-line treatment of CLL. N. Engl. J. Med. 380(22), 2095\u20132103 (2019).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_8_32_2","volume-title":"Prescribing Information","author":"IMBRUVICA (ibrutinib)","year":"2022","unstructured":"IMBRUVICA (ibrutinib). Prescribing Information. Janssen Biotech, Inc, PA, USA (2022)."},{"issue":"4","key":"e_1_3_8_33_2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/oncolo\/oyac260","article-title":"Managing ibrutinib-intolerant patients with B-cell malignancies","volume":"28","author":"Mu\u00f1oz J","year":"2023","unstructured":"Mu\u00f1oz J, Sarosiek S, Castillo JJ. Managing ibrutinib-intolerant patients with B-cell malignancies. Oncologist 28(4), 309\u2013318 (2023).","journal-title":"Oncologist"},{"issue":"12","key":"e_1_3_8_34_2","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1182\/blood-2018-11-846808","article-title":"How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia","volume":"133","author":"Stephens DM","year":"2019","unstructured":"Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood 133(12), 1298\u20131307 (2019).","journal-title":"Blood"},{"issue":"12","key":"e_1_3_8_35_2","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek M","year":"2021","unstructured":"Hallek M, Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am. J. Hematol. 96(12), 1679\u20131705 (2021).","journal-title":"Am. J. Hematol."},{"key":"e_1_3_8_36_2","doi-asserted-by":"crossref","first-page":"720704","DOI":"10.3389\/fonc.2021.720704","article-title":"Monitoring and managing BTK inhibitor treatment-related adverse events in clinical practice","volume":"11","author":"O'Brien SM","year":"2021","unstructured":"O'Brien SM, Brown JR, Byrd JC Monitoring and managing BTK inhibitor treatment-related adverse events in clinical practice. Front. Oncol. 11, 720704 (2021).","journal-title":"Front. Oncol."},{"issue":"2","key":"e_1_3_8_37_2","first-page":"161","article-title":"Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate","volume":"29","author":"Morrison L","year":"2023","unstructured":"Morrison L, Lin D, Benson C Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate. J. Manag. Care Spec. Pharm. 29(2), 161\u2013171 (2023).","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"5","key":"e_1_3_8_38_2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1155\/2015\/862702","article-title":"Use of electronic health records for early detection of high-cost, low back pain patients","volume":"20","author":"Maeng DD","year":"2015","unstructured":"Maeng DD, Stewart WF, Yan X Use of electronic health records for early detection of high-cost, low back pain patients. Pain Res. Manag. 20(5), 234\u2013240 (2015).","journal-title":"Pain Res. Manag."},{"issue":"2","key":"e_1_3_8_39_2","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.3390\/curroncol30020180","article-title":"Cost savings of expedited care with upfront next-generation sequencing testing versus single-gene testing among patients with metastatic non-small cell lung cancer based on current canadian practices","volume":"30","author":"Sheffield BS","year":"2023","unstructured":"Sheffield BS, Eaton K, Emond B Cost savings of expedited care with upfront next-generation sequencing testing versus single-gene testing among patients with metastatic non-small cell lung cancer based on current canadian practices. Curr. Oncol. 30(2), 2348\u20132365 (2023).","journal-title":"Curr. Oncol."},{"issue":"3","key":"e_1_3_8_40_2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.amjcard.2018.10.033","article-title":"Cost implications of anticoagulation strategies after percutaneous coronary intervention among patients with atrial fibrillation (A PIONEER-AF PCI analysis)","volume":"123","author":"Korjian S","year":"2019","unstructured":"Korjian S, Daaboul Y, Lalibert\u00e9 F Cost implications of anticoagulation strategies after percutaneous coronary intervention among patients with atrial fibrillation (A PIONEER-AF PCI analysis). Am. J. Cardiol. 123(3), 355\u2013360 (2019).","journal-title":"Am. J. Cardiol."},{"issue":"25","key":"e_1_3_8_41_2","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin PC","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat. Med. 28(25), 3083\u20133107 (2009).","journal-title":"Stat. Med."},{"issue":"6","key":"e_1_3_8_42_2","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan H","year":"2011","unstructured":"Quan H, Li B, Couris CM Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am. J. Epidemiol. 173(6), 676\u2013682 (2011).","journal-title":"Am. J. Epidemiol."},{"issue":"10","key":"e_1_3_8_43_2","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jama.2015.10725","article-title":"Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism and Death in Patients With Heart Failure With and Without Atrial Fibrillation","volume":"314","author":"Melgaard L","year":"2015","unstructured":"Melgaard L,Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GYH, , Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism and Death in Patients With Heart Failure With and Without Atrial Fibrillation. JAMA. 314(10), 1030 (2015).","journal-title":"JAMA."},{"issue":"2","key":"e_1_3_8_44_2","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","article-title":"2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons","volume":"140","author":"January CT","year":"2019","unstructured":"January CT, Wann LS, Calkins H 2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 140(2), e125\u2013e1 (2019).","journal-title":"Circulation."},{"issue":"1","key":"e_1_3_8_45_2","doi-asserted-by":"crossref","first-page":"e016982","DOI":"10.1136\/bmjopen-2017-016982","article-title":"Economic impact of medication non-adherence by disease groups: a systematic review","volume":"8","author":"Cutler RL","year":"2018","unstructured":"Cutler RL, Fernandez-Llimos F, Frommer M Economic impact of medication non-adherence by disease groups: a systematic review. BMJ Open 8(1), e016982 (2018).","journal-title":"BMJ Open"},{"key":"e_1_3_8_46_2","first-page":"35","article-title":"Adherence and health care costs","volume":"7","author":"Iuga AO","year":"2014","unstructured":"Iuga AO, McGuire MJ. Adherence and health care costs. Risk Manag. Healthcare Pol. 7, 35\u201344 (2014).","journal-title":"Risk Manag. Healthcare Pol."},{"issue":"2","key":"e_1_3_8_47_2","doi-asserted-by":"crossref","first-page":"e56813","DOI":"10.1371\/journal.pone.0056813","article-title":"Patient adherence and persistence with imatinib, nilotinib, dasatinib in clinical practice","volume":"8","author":"Santoleri F","year":"2013","unstructured":"Santoleri F, Sorice P, Lasala R Patient adherence and persistence with imatinib, nilotinib, dasatinib in clinical practice. PLoS ONE 8(2), e56813 (2013).","journal-title":"PLoS ONE"},{"issue":"6","key":"e_1_3_8_48_2","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.amjmed.2019.12.021","article-title":"Medication adherence, health care utilization, and spending among privately insured adults with chronic conditions in the United States, 2010\u20132016","volume":"133","author":"Gillespie CW","year":"2020","unstructured":"Gillespie CW, Morin PE, Tucker JM Medication adherence, health care utilization, and spending among privately insured adults with chronic conditions in the United States, 2010\u20132016. Am. J. Med. 133(6), 690\u2013704.e19 (2020).","journal-title":"Am. J. Med."},{"key":"e_1_3_8_49_2","first-page":"716","article-title":"Validation of real-world data-based endpoint measures of cancer treatment outcomes","volume":"2021","author":"Li Q","year":"2021","unstructured":"Li Q, Zhang H, Chen Z Validation of real-world data-based endpoint measures of cancer treatment outcomes. AMIA Annu. Symp. Proc. 2021, 716\u2013725 (2021).","journal-title":"AMIA Annu. Symp. Proc."},{"issue":"1","key":"e_1_3_8_50_2","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/cpt.2453","article-title":"The friends of cancer research real-world data collaboration pilot 2.0: methodological recommendations from oncology case studies","volume":"111","author":"Rivera DR","year":"2022","unstructured":"Rivera DR, Henk HJ, Garrett-Mayer E The friends of cancer research real-world data collaboration pilot 2.0: methodological recommendations from oncology case studies. Clin. Pharmacol. Ther. 111(1), 283\u2013292 (2022).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"e_1_3_8_51_2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1080\/10428194.2024.2402814","article-title":"Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"66","author":"Shadman M","year":"2025","unstructured":"Shadman M, Salkar M, Srivastava B Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma. Leuk. Lymphoma 66(1), 44\u201353 (2025).","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"e_1_3_8_52_2","doi-asserted-by":"crossref","first-page":"100022","DOI":"10.1016\/j.bneo.2024.100022","article-title":"Impact of ibrutinib dose adjustment on TTNT in first-line CLL\/SLL: a real-world analysis using target trial emulation","volume":"1","author":"Ghosh N","year":"2024","unstructured":"Ghosh N, Wang R, Qureshi ZP Impact of ibrutinib dose adjustment on TTNT in first-line CLL\/SLL: a real-world analysis using target trial emulation. Blood Neoplasia 1(3), 100022 (2024).","journal-title":"Blood Neoplasia"},{"issue":"16","key":"e_1_3_8_53_2","doi-asserted-by":"crossref","first-page":"7537","DOI":"10.1200\/JCO.2023.41.16_suppl.7537","article-title":"Real-world (RW) dosing patterns and outcomes among chronic lymphocytic leukemia (CLL) patients (pts) with or without an ibrutinib (IBR) dose adjustment (DA) in first-line (1L)","volume":"41","author":"Rogers KA","year":"2023","unstructured":"Rogers KA, Lu X, Emond B Real-world (RW) dosing patterns and outcomes among chronic lymphocytic leukemia (CLL) patients (pts) with or without an ibrutinib (IBR) dose adjustment (DA) in first-line (1L). J. Clin. Oncol. 41(16), 7537 (2023).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_8_54_2","doi-asserted-by":"crossref","first-page":"7753","DOI":"10.1182\/blood-2024-201206","article-title":"Overall survival of patients with chronic lymphocytic leukemia treated with frontline bruton's tyrosine kinase inhibitors: an analysis of the United States Veterans Health Administration database","volume":"144","author":"Fitzgerald L","year":"2024","unstructured":"Fitzgerald L, Khan W, Bokun A Overall survival of patients with chronic lymphocytic leukemia treated with frontline bruton's tyrosine kinase inhibitors: an analysis of the United States Veterans Health Administration database. Blood 144, 7753 (2024).","journal-title":"Blood"},{"issue":"1","key":"e_1_3_8_55_2","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1182\/blood-2022-156948","article-title":"Cost-effectiveness analyses of first line ibrutinib versus acalabrutinib versus zanubrutinib followed by second line venetoclax plus rituximab in previously untreated chronic lymphocytic leukemia (CLL) patients","volume":"140","author":"Alrawashdh N","year":"2022","unstructured":"Alrawashdh N, McBride A, Abraham I. Cost-effectiveness analyses of first line ibrutinib versus acalabrutinib versus zanubrutinib followed by second line venetoclax plus rituximab in previously untreated chronic lymphocytic leukemia (CLL) patients. Blood 140(Suppl. 1), 2155\u20132156 (2022).","journal-title":"Blood"},{"key":"e_1_3_8_56_2","doi-asserted-by":"crossref","first-page":"7385","DOI":"10.1182\/blood-2023-181053","article-title":"Real-world treatment patterns and healthcare resource utilization in patients with waldenstr\u00f6m macroglobulinemia initiating first-line treatment with ibrutinib or zanubrutinib","volume":"142","author":"Paludo J","year":"2023","unstructured":"Paludo J, Sarosiek SR, von Keudell GR Real-world treatment patterns and healthcare resource utilization in patients with waldenstr\u00f6m macroglobulinemia initiating first-line treatment with ibrutinib or zanubrutinib. Blood 142, 7385 (2023).","journal-title":"Blood"},{"issue":"10","key":"e_1_3_8_57_2","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s12325-018-0772-3","article-title":"Burden of infections among chronic myeloid leukemia patients receiving dasatinib or nilotinib: a real-world retrospective healthcare claims study in the United States","volume":"35","author":"Seiter K","year":"2018","unstructured":"Seiter K, Latremouille-Viau D, Guerin A Burden of infections among chronic myeloid leukemia patients receiving dasatinib or nilotinib: a real-world retrospective healthcare claims study in the United States. Adv. Ther. 35(10), 1671\u20131685 (2018).","journal-title":"Adv. Ther."},{"issue":"11","key":"e_1_3_8_58_2","doi-asserted-by":"crossref","first-page":"e959","DOI":"10.1016\/j.clml.2022.07.004","article-title":"Real-world persistence and time to next treatment with ibrutinib in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma including patients at high risk for atrial fibrillation or stroke","volume":"22","author":"Narezkina A","year":"2022","unstructured":"Narezkina A, Akhter N, Lu X Real-world persistence and time to next treatment with ibrutinib in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma including patients at high risk for atrial fibrillation or stroke. Clin. Lymph. Myeloma Leuk. 22(11), e959\u2013e971 (2022).","journal-title":"Clin. Lymph. Myeloma Leuk."},{"issue":"8","key":"e_1_3_8_59_2","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1002\/cam4.2268","article-title":"Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States","volume":"8","author":"Kabadi SM","year":"2019","unstructured":"Kabadi SM, Goyal RK, Nagar SP, Kaye JA, Davis KL. Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States. Cancer Med. 8(8), 3803\u20133810 (2019).","journal-title":"Cancer Med."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2024-0210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T14:52:02Z","timestamp":1745333522000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2024-0210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":57,"alternative-id":["10.57264\/cer-2024-0210"],"URL":"https:\/\/doi.org\/10.57264\/cer-2024-0210","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"article-number":"e240210"}}